Semaglutide: Structure, Incretin Pharmacology, and Handling

Three modifications, three problems

Native GLP-1 has a circulating half-life of roughly two minutes. Semaglutide extends this by orders of magnitude through three deliberate structural changes to the GLP-1(7-37) backbone.

First, substitution of alanine at position 8 with α-aminoisobutyric acid (Aib) removes the DPP-4 cleavage site. DPP-4 is the principal route of native GLP-1 inactivation, and this single substitution addresses it.

Second, a C18 fatty diacid is conjugated to Lys26 through a γ-glutamic acid and two short PEG-like spacers. The diacid drives reversible albumin binding, which both shields the peptide from renal filtration and creates a slow-release depot.

Third, Lys34 is substituted with arginine to ensure the fatty acid conjugates at a single defined position rather than producing a heterogeneous mixture.

Receptor pharmacology

Semaglutide is a selective GLP-1 receptor agonist with no meaningful GIP or glucagon receptor activity — the property that distinguishes it from the dual and triple agonists that followed.

The GLP-1 receptor is a class B GPCR signaling primarily through Gαs and cAMP accumulation. Research interest in biased agonism at this receptor concerns the balance between cAMP signaling and β-arrestin recruitment, the latter driving receptor internalization. Reduced β-arrestin recruitment relative to native GLP-1 has been proposed as contributing to sustained signaling.

Receptor distribution extends well beyond pancreatic β-cells — including regions of the hypothalamus and brainstem — which is the anatomical basis for research into central pathways.

Comparative context

Semaglutide is the reference compound against which dual (tirzepatide) and triple (retatrutide) agonists are benchmarked. Comparative work typically examines whether additional receptor engagement produces effects separable from more complete GLP-1 receptor occupancy.

For study design, the relevant distinction is that tirzepatide is built on a GIP backbone with GLP-1 activity added, whereas semaglutide is a GLP-1 analog. They are not the same molecule with an extra receptor bolted on, and dose equivalence between them is not straightforward.

Laboratory handling

Store lyophilized powder at -20°C protected from light. Reconstituted solution is stable at 2-8°C for approximately 30 days.

Reconstitute with bacteriostatic water directed down the vial wall. Do not shake. Fatty-acid-conjugated peptides are particularly prone to aggregation at the air-liquid interface under agitation.

Visible cloudiness or particulate after reconstitution indicates aggregation and the material should not be used for quantitative work.